I agree that this site is using cookies. You can find further informations
here
.
X
Login
My folder (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
Show Desktop-Version
Toggle navigation
Osunkwo, I.
42
results:
Search for persons
X
Format
Online (42)
Mediatypes
Articles (Online) (22)
OpenAccess-fulltext (20)
Languages
english (40)
french (1)
Sorted by: Relevance
Sorted by: Year
?
1
P1495: ETAVOPIVAT TREATMENT FOR UP TO 12 WEEKS IN PATIENTS ..:
Saraf, S.
;
Brown, R. C.
;
Hagar, R. W.
...
HemaSphere. 6 (2022) - p. 1377-1378 , 2022
Link:
https://doi.org/10.1097/..
?
2
P1467: HEALTHCARE PROFESSIONALS (HCP) OPINIONS ON TREATMENT..:
Andemariam, B.
;
James, J.
;
Minniti, C.
...
HemaSphere. 6 (2022) - p. 1349-1350 , 2022
Link:
https://doi.org/10.1097/..
?
3
S131: REGIONAL ASSESSMENT OF THE EXPERIENCES OF HEALTHCARE ..:
Osunkwo, I
;
Andemariam, B
;
Minniti, C
...
HemaSphere. 6 (2022) - p. 17-17 , 2022
Link:
https://doi.org/10.1097/..
?
4
S109: ACTIVATION OF PYRUVATE KINASE-R WITH ETAVOPIVAT (FT-4..:
Telen, M
;
Saraf, S
;
Cruz, K
...
HemaSphere. 6 (2022) - p. 5-5 , 2022
Link:
https://doi.org/10.1097/..
?
5
Expérience en vie réelle chez des patients atteints de drép..:
Andemariam, B.
;
Osunkwo, I.
;
Idowu, M.
...
La Revue de Médecine Interne. 43 (2022) - p. A200-A201 , 2022
Link:
https://doi.org/10.1016/..
?
6
HEALTHCARE PROFESSIONAL (HCP) PERCEPTIONS OF SICKLE CELL DI..:
Abboud, M.R.
;
James, J.
;
Ramscar, N.
..
Hematology, Transfusion and Cell Therapy. 42 (2020) - p. 45 , 2020
Link:
https://doi.org/10.1016/..
?
7
PRO82 IMPACT OF SICKLE CELL DISEASE SYMPTOMS ON PATIENTS' D..:
Osunkwo, I.
;
Andemariam, B.
;
Inusa, B.
...
Value in Health. 23 (2020) - p. S343 , 2020
Link:
https://doi.org/10.1016/..
?
8
USE OF OPIOIDS AND BURDEN OF DISEASE IN PATIENTS (PTS) WITH..:
Pita, M.
;
James, J.
;
Forny, S.
..
Hematology, Transfusion and Cell Therapy. 42 (2020) - p. 59 , 2020
Link:
https://doi.org/10.1016/..
?
9
Evaluating the Protective Role of Racial Identity in Childr..:
Lim, C. S.
;
Welkom, J. S.
;
Cohen, L. L.
.
Journal of Pediatric Psychology. 37 (2012) 8 - p. 832-842 , 2012
Link:
https://doi.org/10.1093/..
?
10
Evidence for Quantitative and Functional Immune Deviation i..:
Kean, L.S.
;
Sen, S.
;
Felder, M.A.
...
Biology of Blood and Marrow Transplantation. 18 (2012) 2 - p. S275 , 2012
Link:
https://doi.org/10.1016/..
?
11
A randomized double blind, placebo controlled study of vita..:
Osunkwo, I.
;
Ziegler, T.
;
Alvarez, J.
...
The Journal of Pain. 13 (2012) 4 - p. S73 , 2012
Link:
https://doi.org/10.1016/..
?
12
Tacrolimus (FK-506) and mycophenolate mofetil (MMF) GVHD pr..:
Bessmertny, O.
;
Farris, K.
;
van de Ven, C.
...
Biology of Blood and Marrow Transplantation. 10 (2004) - p. 103 , 2004
Link:
https://doi.org/10.1016/..
?
13
94 Tacrolimus (FK-506) and mycophenolate mofetil (MMF) GVHD..:
Bessmertny, O.
;
Osunkwo, I.
;
Harrison, L.
...
Biology of Blood and Marrow Transplantation. 9 (2003) 2 - p. 93 , 2003
Link:
https://doi.org/10.1016/..
?
14
P-004: HEALTH CARE TRANSITION (HCT) FOR SICKLE CELL DISEASE..:
I., OSUNKWO
;
J., CORNETTE
;
C., COURTLANDT
...
HemaSphere. 6 (2022) - p. 18-18 , 2022
Link:
https://doi.org/10.1097/..
?
15
O-03: ETAVOPIVAT TREATMENT FOR UP TO 12 WEEKS IN PATIENTS W..:
M., TELEN
;
R., BROWN
;
R., HAGAR
...
HemaSphere. 6 (2022) - p. 02-03 , 2022
Link:
https://doi.org/10.1097/..
1-15